Popova V, Vazhev Z, Geneva-Popova M, Batalov A (2019) Comparison of RANKL expression, inflammatory markers, and cardiovascular risk in patients with acute coronary syndrome with and without rheumatoid arthritis. Rheumatol Int 39:1723–1732. https://doi.org/10.1007/s00296-019-04367-9
Article CAS PubMed Google Scholar
Kirilova E, Kirilov N, Vladeva S (2019) AB0838 comparison of the characteristics of the osteoporotic patients with and without rheumatoid arthritis through radiofrequency echographic multi spectrometry. Ann Rheum Dis 78:1888–1889. https://doi.org/10.1136/annrheumdis-2019-eular.2203
Mayou R (1977) Compliance with Therapeutic Regimens Edited by Sackett DL and Haynes BR Baltimore and London: Johns Hopkins University Press (1976) Pp xiv 287, Index 5 pp. Br J Psychiatry 131: 214–214. https://doi.org/10.1192/S0007125000016251
World Health Organization. Adherence to long-term therapies: evidence for action. 2003. www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed 20.08.2023
Haynes RB, McDonald H, Garg AX, Montague P (2002) Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2:000011. https://doi.org/10.1002/14651858.CD000011
Garcês S, Demengeot J (2018) The immunogenicity of biologic therapies. Curr Probl Dermatol 53:37–48. https://doi.org/10.1159/000478077
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699. https://doi.org/10.1136/annrheumdis-2019-216655
Article CAS PubMed Google Scholar
Harrold LR, Andrade SE (2009) Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 38:396–402. https://doi.org/10.1016/j.semarthrit.2008.01.011
Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L (2010) Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 10:1367–1378. https://doi.org/10.1517/14712598.2010.510508
Article CAS PubMed Google Scholar
Salt E, Frazier SK (2010) Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs 29:260–275. https://doi.org/10.1097/NOR.0b013e3181e5c2c9
Article PubMed PubMed Central Google Scholar
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47. https://doi.org/10.1111/j.1524-4733.2007.00213.x
Neycheva S, Naseva E, Batalov Z et al (2023) Adherence to biological therapies in patients with rheumatoid arthritis: a retrospective cohort study. Rheumatol Int 43:1287–1296. https://doi.org/10.1007/s00296-023-05327-0
Article CAS PubMed Google Scholar
Kay J, Upchurch KS (2012) ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 51:5–9. https://doi.org/10.1093/rheumatology/kes279
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509. https://doi.org/10.1136/annrheumdis-2013-204573
Article CAS PubMed Google Scholar
World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194. https://doi.org/10.1001/jama.2013.281053
World Health Organization (2013) Ethical issues in patient safety research: interpreting existing guidance. IOP Publishing World Health Organization. https://apps.who.int/iris/handle/10665/85371. Accessed 04 Apr 2023
Harley CR, Frytak JR, Tandon N (2003) Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 9:136–143
Murage M, Tongbram V, Feldman S, Malatestinic W, Larmore C, Muram T, Araujo A (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Preference Adher 12:1483–1503. https://doi.org/10.2147/ppa.s167508
Rubbert-Roth A, Szabó MZ, Kedves M et al (2019) Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. https://doi.org/10.1016/j.autrev.2019.102398
Jørgensen TS, Kristensen LE, Christensen R, Bliddal H, Lorenzen T, Hansen MS, Lund Hetland M (2015) Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology. https://doi.org/10.1093/rheumatology/kev216
Leffers HC, Ostergaard M, Glintborg B et al (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70:1216–1222. https://doi.org/10.1136/ard.2010.140129
Article CAS PubMed Google Scholar
Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA (2010) Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value in Health 13:805–812. https://doi.org/10.1111/j.1524-4733.2010.00764.x
Article CAS PubMed Google Scholar
Aaltonen K, Joensuu J, Pirilä L, Kauppi M, Uutela T, Varjolahti-Lehtinen T, Sokka T (2016) Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol 46:359–363. https://doi.org/10.1080/03009742.2016.1234641
Article CAS PubMed Google Scholar
Chu L-H, Kawatkar AA, Gabriel SE (2015) Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients. Clin Ther 37:660–666. https://doi.org/10.1016/j.clinthera.2014.10.022
Marras C, Monteagudo I, Salvador G, de Toro FJ, Escudero A, Alegre-Sancho JJ, Raya E, Ortiz A, Carmona L, Mestre Y, CeaCalvo L, Calvo-Alen J (2017) Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study. Rheumatol Int 37:1195–1202. https://doi.org/10.1007/s00296-017-3737-y
Tkacz J, Ellis L, Bolge SC, Meyer R, Brady BL, Ruetsch C (2014) Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther 36:737–747. https://doi.org/10.1016/j.clinthera.2014.02.019
Article CAS PubMed Google Scholar
Müller R, Kallikorm R, Põlluste K, Lember M (2011) Compliance with treatment of rheumatoid arthritis. Rheumatol Int 32:3131–3135. https://doi.org/10.1007/s00296-011-2162-x
Souto A, Maneiro JR, Gómez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology 55:523–534. https://doi.org/10.1093/rheumatology/kev37
Article CAS PubMed Google Scholar
Fautrel B, Belhassen M, Hudry C et al (2020) Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients. Joint Bone Spine 87:137–139. https://doi.org/10.1016/j.jbspin.2019.10.004
Du Pan SM, Scherer A, Gabay C, Finckh A (2012) Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 71:997–999. https://doi.org/10.1136/annrheumdis-2011-200882
Article CAS PubMed Google Scholar
Forsblad-dElia H, Bengtsson K, Kristensen LE, Jacobsson LT (2015) Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology 54:1186–1193. https://doi.org/10.1093/rheumatology/keu455
Article CAS PubMed Google Scholar
Borah BJ, Huang X, Zarotsky V, Globe D (2009) Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 25:1365–1377. https://doi.org/10.1185/03007990902896386
Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A (2007) Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int 27:743–746. https://doi.org/10.1007/s00296-006-0299-9
Gadallah MA, Boulos DNK, Dewedar S, Gebrel A, Morisky DE (2015) Assessment of Rheumatoid Arthritis Patients’ Adherence to Treatment. Am J Med Sci 349:151–156. https://doi.org/10.1097/maj.0000000000000376
Joplin S, van der Zwan R, Joshua F, Wong PK (2015) Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int 2015:150658. https://doi.org/10.1155/2015/150658
Article PubMed PubMed Central Google Scholar
Gallo G, Brock F, Kerkmann U, Kola B, Huizinga TWJ (2016) Efficacy of etanercept in combination with methotrexate in moderate-to severe rheumatoid arthritis is not dependent on methotrexate dosage. RMD Open 2:e000186
Comments (0)